Status:
UNKNOWN
Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making
Lead Sponsor:
Peking University
Conditions:
Gastric Cancer
Eligibility:
All Genders
Phase:
NA
Brief Summary
The purpose of the study is to evaluate the maximal cycle of effective neoadjuvant chemotherapy for resectable gastric cancer, to determine what is the best cycle of neoadjuvant chemotherapy for the p...
Detailed Description
The study is a non-randomized clinical trial. The protocol has been approved by the Ethics Committee of Beijing Cancer Hospital. MRI and enhanced CT are used to evaluate the clinical response of the t...
Eligibility Criteria
Inclusion
- Histologically proven adenocarcinoma of the stomach
- Clinical cT2N+M0,or cT3-4a/N+M0 disease, confirmed by upper gastrointestinal endoscopy and abdominal computed tomography (CT) and MRI and laparoscopy.
- Receive neoadjuvant chemotherapy in clinical
Exclusion
- Contraindication for chemotherapy
- Contraindication for surgery
- Clinically apparent distant metastasis
Key Trial Info
Start Date :
January 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 3 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03413514
Start Date
January 3 2018
End Date
January 3 2023
Last Update
January 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital
Beijing, Beijing Municipality, China, 100142